Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Pharmaceuticals & Biotechnology | Small Cap
Health Score : 5.31Remus Pharmaceuticals shows a mixed financial picture. The company demonstrates significant strengths in solvency, growth, and coverage ratios, suggesting a solid capital structure and promising expansion. However, it struggles with liquidity, efficiency, financial metrics, and profitability, indicating potential challenges in short-term financial management and revenue generation. While the company's solvency is strong, its ability to convert assets into profits and manage short-term obligations appears weak. The healthcare industry's dynamic nature means Remus Pharmaceuticals needs to address these weaknesses to maintain a competitive edge and ensure long-term sustainability. The company shows promise with interest coverage, suggesting it can comfortably handle its debt obligations. The company shows promise with growth in operating profit, EPS, and assets, which could translate to enhanced shareholder value if properly managed. However, the low scores in liquidity, efficiency and profitability need to be addressed for balanced financial health.
Health Score : 5.31Remus Pharmaceuticals shows a mixed financial picture. The company demonstrates significant strengths in solvency, growth, and coverage ratios, suggesting a solid capital structure and promising expansion. However, it struggles with liquidity, efficiency, financial metrics, and profitability, indicating potential challenges in short-term financial management and revenue generation. While the company's solvency is strong, its ability to convert assets into profits and manage short-term obligations appears weak. The healthcare industry's dynamic nature means Remus Pharmaceuticals needs to address these weaknesses to maintain a competitive edge and ensure long-term sustainability. The company shows promise with interest coverage, suggesting it can comfortably handle its debt obligations. The company shows promise with growth in operating profit, EPS, and assets, which could translate to enhanced shareholder value if properly managed. However, the low scores in liquidity, efficiency and profitability need to be addressed for balanced financial health.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
41.33
Industry Median
30.91
Small Cap Median
28.64
P/E RATIO
27.61
P/B RATIO
2.91
Industry Median
3.69
Small Cap Median
3.11
P/S RATIO
1.17
Industry Median
3.74
Small Cap Median
3.02
Others
PEG RATIO
0.00
EV/EBITDA RATIO
15.77
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹866.6 as on Sep 1, 2026.
Growth Score : 6.00The company demonstrates strong growth in operating profit, EPS, and assets, signaling promising expansion and potential for enhanced shareholder value. However, low revenue and net income growth rates indicate areas needing attention to ensure balanced and sustainable growth. These strengths suggest a positive trajectory for the company's future. The company's growth in operating profit, EPS, and assets can lead to increased shareholder value.
Revenue Growth RatePoorOperating Profit Growth RateExcellentEarnings Per Share (EPS) GrowthExcellentAsset Growth RateExcellentNet Income Growth RatePoor| Growth Ratios | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue Growth Rate | 191.08 | 37.74 |
| Operating Profit Growth Rate | 58.62 | 23.91 |
| Earnings Per Share (EPS) Growth | 39.29 | 27.39 |
| Asset Growth Rate | 30.03 | 33.72 |
| Net Income Growth Rate | 58.33 | 21.05 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Accent Microcell Ltd | 7.96 | 24.25 | Neutral | 57.00 | 18.28 | 44.00 |
| 2 | Lincoln Pharmaceuticals Ltd | 7.31 | 13.89 | Neutral | 98.00 | 43.88 | 88.00 |
| 3 | Kilitch Drugs (India) Ltd | 7.12 | 22.83 | Neutral | 37.00 | 9.27 | 30.00 |
| 4 | NGL Fine Chem Ltd | 6.98 | 34.11 | Neutral | 73.00 | 67.39 | 48.00 |
| 5 | Sakar Healthcare Ltd | 6.89 | 70.49 | Highly Overvalued | 69.00 | 13.70 | 30.00 |
| 6 | Medico Remedies Ltd | 6.61 | 37.70 | Overvalued | 17.00 | 1.58 | 13.00 |
| 7 | Kopran Ltd | 6.60 | 40.82 | Undervalued | 62.00 | 6.30 | 26.00 |
| 8 | SMS Lifesciences India Ltd | 6.59 | 22.25 | Undervalued | 45.00 | 58.80 | 19.00 |
| 9 | Infinium Pharmachem Ltd | 6.42 | 33.97 | Neutral | 22.00 | 6.43 | 14.00 |
| 10 | Medicamen Biotech Ltd | 5.73 | 37.61 | Neutral | 20.00 | 6.94 | 10.00 |
| 11 | Albert David Ltd | 5.63 | -333.98 | Neutral | 5.00 | -2.62 | -1.00 |
| 12 | Zim Laboratories Ltd | 5.41 | 108.20 | Neutral | 30.00 | 1.11 | 6.00 |
| 13 | Remus Pharmaceuticals Ltd | 5.31 | 27.61 | Neutral | 57.00 | 20.97 | 46.00 |
| 14 | Ind-Swift Laboratories Ltd | 4.95 | 77.18 | Neutral | 45.00 | 4.89 | 41.00 |
| 15 | Venus Remedies Ltd | 4.83 | 23.37 | Neutral | 147.00 | 74.30 | 103.00 |
| 16 | Wanbury Ltd | 4.65 | 27.30 | Neutral | 88.00 | 15.98 | 43.00 |
| 17 | Nectar Lifescience Ltd | 3.83 | -0.80 | Neutral | -59.00 | -2.95 | -293.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
No Stock Reports Available at This Moment.
Remus Pharmaceuticals Ltd is an Ahmedabad-based pharmaceutical company incorporated in 2015, primarily engaged in the marketing, trading, and distribution of a diverse portfolio of human and veterinary pharmaceutical products. It focuses on domestic and international markets, catering to various therapeutic areas through third-party manufacturing.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Remus Pharmaceuticals Ltd's P/E ratio (TTM) is 41.33, compared to the industry median of 30.91 and large cap median of 28.64.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Remus Pharmaceuticals Ltd's P/B ratio is 2.91, compared to the industry median of 3.69 and large cap median of 3.11.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Remus Pharmaceuticals Ltd's P/S ratio is 1.17, compared to the industry median of 3.74 and large cap median of 3.02.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Remus Pharmaceuticals Ltd's PEG ratio is 1.25.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Remus Pharmaceuticals Ltd's EV/EBITDA ratio is 15.77.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Remus Pharmaceuticals Ltd's ROE is 13.11%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Remus Pharmaceuticals Ltd's ROA is 9.84%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Remus Pharmaceuticals Ltd's ROCE is 17%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Remus Pharmaceuticals Ltd's operating margin is 6.67%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Remus Pharmaceuticals Ltd's net margin is 5.39%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Remus Pharmaceuticals Ltd's current ratio is 1.27.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Remus Pharmaceuticals Ltd's debt-to-equity ratio is 0.03.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Remus Pharmaceuticals Ltd's interest coverage ratio is 60.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Remus Pharmaceuticals Ltd's DPS is ₹0.63.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Remus Pharmaceuticals Ltd's EPS is 27.39.
(Source line: "Ratios as of 26 Sept 2026, based on last traded price of ₹866.60. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 2015
Headquarters: Ahmedabad, Gujarat
Core Offerings: Human pharmaceutical products, Veterinary pharmaceutical products, Active Pharmaceutical Ingredients (APIs)
Stock Listing: NSE (REMUS), BSE ({bse})
Promoter: Chetan Mugatlal Chaudhari, Ajitkumar Chhabaria, Priyanka Chetan Chaudhari
Remus Pharmaceuticals Ltd was incorporated in November 2015, establishing its presence in the pharmaceutical trading and distribution sector. The company steadily expanded its product portfolio and distribution network, focusing on both human and veterinary segments. A key milestone was its successful IPO in March 2023, listing on NSE and BSE, which provided capital for further growth and market penetration.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Human Pharmaceutical Products | 75% (Approx.) | Operating Profit |
| Veterinary Pharmaceutical Products | 20% (Approx.) | Operating Profit |
| Active Pharmaceutical Ingredients (APIs) | 5% (Approx.) | Operating Profit |
Human Pharmaceutical Products: Includes a wide array of formulations like tablets, capsules, injections, and syrups, across therapeutic areas such as anti-infectives, pain management, cardiology, and dermatology.
Veterinary Pharmaceutical Products: Offers medicines for livestock and poultry, encompassing antibiotics, antiparasitics, vitamins, and feed supplements to support animal health and well-being.
Active Pharmaceutical Ingredients (APIs): Engaged in the trading and distribution of various APIs, serving as critical raw materials for pharmaceutical manufacturing by other companies.
Mr. Chetan Mugatlal Chaudhari (Chairman & Managing Director): A first-generation entrepreneur with over 15 years of experience in the pharmaceutical industry, he spearheads the company's strategic direction, business development, and overall growth initiatives.
No major subsidiaries reported.
No major recent corporate actions on record.
The Remus Pharmaceuticals Ltd share price today is ₹866.60 on NSE (REMUS), as of 26 Sept 2026.
As of 26 Sept 2026, Remus Pharmaceuticals Ltd share price is ₹866.60, with previous close ₹866.60. Today's range is ₹866.60 to ₹866.60. The 52-week range is ₹580 to ₹1007.
As of today, Remus Pharmaceuticals Ltd's market cap is ₹996.59 crore (Small Cap).
Remus Pharmaceuticals Ltd's current P/E ratio is 41.33, compared to the PHARMACEUTICALS & BIOTECHNOLOGY sector average of 31.
Remus Pharmaceuticals Ltd's current P/B ratio is 2.91.
Remus Pharmaceuticals Ltd's current dividend yield is 0.07%. Last dividend of ₹0.00 per share was declared on N/A.
Remus Pharmaceuticals Ltd's EPS (TTM) is ₹27.39.
Remus Pharmaceuticals Ltd is an Ahmedabad-based pharmaceutical company incorporated in 2015, primarily engaged in the marketing, trading, and distribution of a diverse portfolio of human and veterinary pharmaceutical products. It focuses on domestic and international markets, catering to various therapeutic areas through third-party manufacturing.
Remus Pharmaceuticals Ltd is promoted by Chetan Mugatlal Chaudhari, Ajitkumar Chhabaria, Priyanka Chetan Chaudhari, holding 70.95% as of 26 Sept 2026.
Remus Pharmaceuticals Ltd is listed on NSE (REMUS) and BSE ({bse}). Its next quarterly results are expected on November 2024.
